AssetMark Inc’s abrdn Life Sciences Investors HQL Stock Holding History

AssetMark Inc’s Portfolio HQL Stock Details HQL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$7.52K	Buy	376 +111	+42%	+$1.96K	﹤0.01%	2559
2026 Q1	$4.31K	Hold	265	–	–	﹤0.01%	2622
2025 Q4	$4.45K	Hold	265	–	–	﹤0.01%	2504
2025 Q3	$4.11K	Hold	265	–	–	﹤0.01%	2410
2025 Q2	$3.4K	Buy	+265	New	+$3.27K	﹤0.01%	2256

Other funds holding HQL

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

PCM

Penserra Capital Management Orinda, California $13B AUM 71.84% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return

LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $65.2B AUM 39.42% 1-Year Est. Return

NIM

Needham Investment Management New York $3.33B AUM 163.16% 1-Year Est. Return

FHA

Flagship Harbor Advisors Boston, Massachusetts $2.61B AUM 23.21% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

AAM

Advisors Asset Management Monument, Colorado $6.56B AUM 35.09% 1-Year Est. Return

1WA

180 Wealth Advisors Federal Way, Washington $997M AUM 47.84% 1-Year Est. Return

AssetMark Inc's HQL Position: Q2 2026 in Review

AssetMark Inc increased its abrdn Life Sciences Investors (HQL) stake by 42% in Q2 2026, buying an estimated $1.96K and bringing the position to 376 shares worth $7.52K. The position accounts for ﹤0.01% of the portfolio, ranked #2559.

AssetMark Inc first reported a position in HQL in Q2 2025 and has held it in 5 quarters since. 83 funds tracked by Wall St. Rank hold HQL as of Q2 2026.

AssetMark Inc held 376 shares of abrdn Life Sciences Investors worth $7.52K as of Q2 2026.
AssetMark Inc bought 111 abrdn Life Sciences Investors shares in Q2 2026, an estimated $1.96K.
abrdn Life Sciences Investors made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #2559 holding.
AssetMark Inc first reported a position in abrdn Life Sciences Investors in Q2 2025 and has held it in 5 quarters since.
83 funds tracked by Wall St. Rank held abrdn Life Sciences Investors as of Q2 2026.

Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.